You are here
Interview with Dr. Benjamin Segal: Neurodegenerative process and the genetics of progressive MS
This interview highlights the first stand-alone ACTRIMS Forum. The focus of the meeting was progressive MS. The treatment landscape for relapsing-remitting MS has improved dramatically over the last 20 years, but there is still no effective treatments for progressive MS. There are 2 types of progressive MS; primary progressive MS, which start as a slow decline from the beginning of the disease course, and secondary progressive MS, which follows relapse-remitting MS.
Dr. Segal discusses some of the issues of progressive MS that will be discussed at ACTRIMS Forum 2016. For example, the role of inflammation in progressive MS may behave differently than other kinds of MS. The neurodegenerative process of progressive MS will also be presented. The genetics of progressive MS and how it differs from relapse-remitting MS will be discussed. Another important topic that will be covered includes the determination of appropriate clinical trial endpoints in trials of patients with progressive MS. Lastly, the meeting will highlight the work of young investigators.
Dr. Benjamin Segal, Holtom-Garrett Professor of Neurology, Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA
This interview was recorded at ACTRIMS 2016, February 18-20, 2016, New Orleans, USA.